NICE TAs

19/06/2025

TA1072: Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)

18/06/2025

TA1070: Spesolimab for treating generalised pustular psoriasis flares

04/06/2025

TA1067: Linzagolix for treating symptoms of endometriosis

04/06/2025

TA1069: Efgartigimod for treating antibody-positive generalised myasthenia gravis

03/06/2025

TA1066: Somapacitan for treating growth hormone deficiency in people 3 to 17 years

28/05/2025

TA1065: Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency

19/05/2025

TA596: Risankizumab for treating moderate to severe plaque psoriasis

15/05/2025

TA1063: Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment

13/05/2025

TA1062: Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor

08/05/2025

TA1060: Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer

07/05/2025

TA1059: Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma

16/04/2025

TA1056: Molnupiravir for treating COVID-19

16/04/2025

TA1055: Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

16/04/2025

TA1057: Relugolix–estradiol–norethisterone for treating symptoms of endometriosis

15/04/2025

TA1054: Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over

15/04/2025

TA1053: Cladribine for treating active relapsing forms of multiple sclerosis

02/04/2025

TA1051: Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over

27/03/2025

TA1050: Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over

27/03/2025

TA1048: Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable

27/03/2025

TA1049: Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia